Peritoneal Dialysis Complication Clinical Trial
Official title:
Influence of Dialysate Temperature on Peritoneal Creatinine Clearance in Patients in Peritoneal Dialysis
Patients on continuous ambulatory peritoneal dialysis (PD) are encouraged to warm dialysate to 37°C before peritoneal infusion; main international PD guidelines do not provide specific recommendation, and patients generally warm dialysate batches partially or do not warm them at all. Warming of dialysate is a time-consuming procedure, not free from potential risks (i.e. degradation of glucose), and should be justified by a clear clinical benefit. The investigators designed a single blind randomized controlled trial where PD patients were randomized to receive a peritoneal equilibration test either with dialysate at a controlled temperature of 37°C (intervention group) or with dialysate warmed with conventional methods (control group). Primary end-point was a higher peritoneal creatinine clearance in patients in the intervention group.
Peritoneal dialysis (PD) currently represents the main choice for home renal replacement
treatment for patients with end stage renal disease. One of the limitations of PD technique
is represented by the difficulty in achieving target dialytic clearances and PD adequacy for
some patients, especially with increasing PD vintage. A potentially relevant issue in PD
clearances is the effect of dialysate temperature on depuration. Indeed, it is common for
clinicians to advise patients in Continuous Ambulatory Peritoneal Dialysis (CAPD) to warm the
dialysate before infusion into the peritoneal cavity, with different methods (microwave oven,
warming cabin, warming pad). Nevertheless, main international PD guidelines do not provide
specific recommendations on this topic. Only guidelines from the British Columbia Renal
Agency (Canada) dedicate a specific chapter to the temperature of dialysate, recommending its
warming to 37°C before peritoneal infusion, mainly in order to avoid an "uncomfortable
lowering of body temperature". On the other hand, warming of PD batches could lead to hot
spots formation inside the batch, especially with microwaves, and to degradation of glucose
leading to the formation of toxic glucose degradation products (GDPs). Also, notable
differences in room temperature exist according to geographical latitude and year season, and
there are no clear and detailed reports in the literature regarding intolerable effects of
the infusion of dialysate at room temperature. It must be acknowledged that it is common
practice for patients to warm dialysate batches only partially or not to warm them at all.
Moreover, warming pads that are most commonly used by CAPD patients do not effectively warm
the dialysate up to 37°C. In the Peritoneal Dialysis Unit at Azienda
Ospedaliero-Universitaria di Modena, it was recently observed that average dialysate
temperature at infusion was 31.1°C, even if the pad was calibrated to 37°C [unpublished
data]. With respect to the effects on toxins clearances through the peritoneal membrane, a
higher dialysate temperature could theoretically favor vasodilation of peritoneal membrane
microcirculation, potentially increasing the passage of substances. Severe microcirculatory
dysfunction has been reported in PD patients and any intervention designed to ameliorate
microcirculatory flow at peritoneal level could be beneficial. Surprisingly, reports
regarding the effects of dialysate temperature on peritoneal clearances in PD in humans are
surprisingly scarce. In 1967 Gross et al reported an increase in the exchange of substances
between peritoneal fluid and blood upon warming of the PD fluid to 37°C (compared to 20°C) in
a patient treated with intermittent peritoneal dialysis; the increase in urea clearance with
the 37°C solution was 35% on average. In contrast, Indraprasit et al did not encounter
differences in peritoneal creatinine clearance utilizing dialysate at room temperature
(27-31°C) and warmed at 37°C in a group of 18 patients in PD. Confirmation of the effects of
dialysate temperature on peritoneal clearances would be of great interest in order to
maximize the depurative potential of PD and to justify patients' effort to warm the batches.
In order to determine the real effects of dialysate temperature on peritoneal clearances and
transport characteristics, abdominal discomfort and vital signs, the investigators designed a
randomized controlled trial comparing two strategies of peritoneal dialysate warming.
Study design and participants PD patients, both in CAPD and automated PD, in regular
follow-up at the Nephrology Unit of the University Hospital of Modena, were randomized to
receive a single dialysis exchange, either with dialysate at a controlled temperature of 37°C
(intervention group) or with dialysate at warmed with conventional methods at uncontrolled
temperature (control group). Randomization was generated through the use of the Random
Allocation software11.
Primary end-point of our study was peritoneal creatinine clearance. Secondary end-points
were: peritoneal urea clearance, creatinine and urea mass transfer area coefficient (MTAC),
abdominal discomfort, blood pressure and body temperature.
A power analysis was performed while designing the study using the few data available in the
literature; setting the alpha-error level at 0.05 for a 2-tailed t-test with a statistical
power of 95% (beta-error 0.05) the estimated sample needed was 14 patients (7 per group).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04034628 -
Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion
|
||
Completed |
NCT03569410 -
The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients
|
N/A | |
Enrolling by invitation |
NCT05250752 -
Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment
|
Phase 2 | |
Recruiting |
NCT03563898 -
Feasibility and Safety in the Management of Fluid Overload in Peritoneal Dialysis Patients Through Sweat Stimulation With the Use of Portable Sauna Bath, Pilot Study
|
N/A | |
Recruiting |
NCT03046511 -
Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter.
|
Phase 3 | |
Not yet recruiting |
NCT05224466 -
Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients
|
||
Completed |
NCT03458819 -
EMT in Peritoneal Dialysis Patients
|
||
Recruiting |
NCT06398977 -
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT06045858 -
SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN PERITONEAL DIALYSIS PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION: A PROSPECTIVE, RANDOMISED, OPEN-LABEL, BLINDED END-POINT TRIAL (APIDP2)
|
Phase 3 | |
Active, not recruiting |
NCT04034966 -
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
|
N/A | |
Completed |
NCT04923295 -
The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT05715814 -
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
|
Phase 3 | |
Recruiting |
NCT03148002 -
Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation
|
Phase 4 | |
Recruiting |
NCT04572724 -
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
|
Phase 4 | |
Completed |
NCT05797181 -
The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment
|
N/A | |
Recruiting |
NCT01893710 -
International (Pediatric) Peritoneal Biobank
|
||
Completed |
NCT03382444 -
The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD
|
||
Completed |
NCT04046263 -
Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
|
Phase 4 | |
Completed |
NCT03759002 -
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
|
||
Completed |
NCT04176627 -
Assessing Fluid Status of Peritoneal Dialysis Patients With Assistance of Lung Ultrasound
|